Squamous Cell Carcinoma of the Oral Cavity Clinical Trial
Official title:
Evaluation of Local Control in Buccinator Muscle Excision With the Skin Versus Buccinator Muscle Excision Without the Skin in Buccal Squamous Cell Carcinoma: A Randomized Clinical Trial.
Evaluation of local control in buccinator muscle excision with the skin versus buccinator muscle excision without the skin in buccal squamous cell carcinoma: A randomized clinical trial.
Preoperative Multi Slice CT scan or MRI carried out for evaluation the lymph node of the
neck. Also, ultrasound carried out for measuring the depth of invasion of the tumour in the
cheek (The invasion in the buccinator muscle).
- Under general anaesthesia, the buccal squamous cell carcinoma which invaded the
buccinator muscle will be excised with the skin of the cheek. This will be done by a
safety margins in the soft tissue and the mandible may be resected according to the plan
and the invasion of the tumour.
- A neck dissection will be done in all cases of negative or positive neck lymph node.
- Reconstruction of the soft tissue will be done immediately by a major pectorals flap
with the skin, also bony reconstruction may be done by a reconstructed plate at the time
of surgery then the patients will be prepared for bone graft in another surgery.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05540899 -
Testing the Safety of Giving a Standard Dose of Radiation Over a Shorter Period of Time for Patients Who Had Surgery for Intermediate-Risk Head and Neck Cancer
|
Phase 1 | |
| Completed |
NCT01108042 -
TPF-Induction Chemotherapy of Oropharyngeal and Cavity of the Mouth Cancer
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT06380686 -
Head and Neck Carcinoma Clinical Research Platform for Molecular and Blood-based Biomarkers, Treatment and Outcome
|
||
| Active, not recruiting |
NCT03721757 -
CA209-891: Neoadjuvant and Adjuvant Nivolumab as Immune Checkpoint Inhibition in Oral Cavity Cancer
|
Phase 2 | |
| Completed |
NCT02873819 -
Safety and Efficacy Study of GL-0817 (With Cyclophosphamide) for the Prevention of Recurrence of Squamous Cell Carcinoma of the Oral Cavity
|
Phase 2 | |
| Active, not recruiting |
NCT04387682 -
Myeloid-derived Suppressor Cells (MDSCs) in OSCC Patients
|
N/A | |
| Completed |
NCT01321892 -
Ex Vivo Multimodal Imaging of Upper Aerodigestive Epithelium
|
N/A | |
| Completed |
NCT01636544 -
Infectious Aetiology of Potentially Malignant Disorders and Squamous Cell Carcinomas of the Oral Cavity
|
N/A | |
| Not yet recruiting |
NCT05608369 -
Vorinostat in Combination With Chemoradiation in Locally Advanced HPV Negative HNSCC
|
Phase 2 | |
| Withdrawn |
NCT04831450 -
Phase 2 Trial of Maintenance Cemiplimab for Head and Neck Squamous Cell Carcinoma (HNSCC)
|
Phase 2 | |
| Recruiting |
NCT04191460 -
Fluorescence-guided Surgery Using cRGD-ZW800-1 in Oral Cancer
|
Phase 2 | |
| Recruiting |
NCT06030440 -
De-Intensification of Postoperative Radiotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck
|
Phase 2/Phase 3 | |
| Terminated |
NCT01077869 -
A Feasibility Study on the Use of F-18-FDG-PET and Optical Imaging in Evaluation of Radiation-induced Oral Mucositis
|
Phase 1 | |
| Completed |
NCT02609386 -
IRX-2 Regimen in Patients With Newly Diagnosed Stage II, III, or IVA Squamous Cell Carcinoma of the Oral Cavity
|
Phase 2 | |
| Not yet recruiting |
NCT05452408 -
Antitumor-B KAC PK Study
|
Phase 1 | |
| Terminated |
NCT02331875 -
Efficacy Study of Pre-operative IPH2201 in Patients With Squamous Cell Carcinoma of the Oral Cavity
|
Phase 1/Phase 2 | |
| Completed |
NCT01265849 -
Efficacy and Safety Study of Leukocyte Interleukin,Injection (LI) to Treat Cancer of the Oral Cavity
|
Phase 3 | |
| Active, not recruiting |
NCT03370276 -
Cetuximab & Nivolumab in Patients With Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma
|
Phase 1/Phase 2 | |
| Completed |
NCT03575598 -
Sitravatinib (MGCD516) and Nivolumab in Oral Cavity Cancer Window Opportunity Study
|
Early Phase 1 | |
| Active, not recruiting |
NCT03459729 -
Pharmacokinetic (PK) Analysis of Antitumor B in Patients With Oral Cancer
|
Early Phase 1 |